{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:06:31Z","timestamp":1784549191884,"version":"3.55.0"},"reference-count":17,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  Background: Clostridioides difficile infection (CDI) is a significant complication in patients with inflammatory bowel disease (IBD), often associated with higher recurrence rates, increased morbidity, and complex therapeutic decision-making. The optimal antibiotic regimen for CDI in IBD remains uncertain.  Objective: To evaluate the efficacy of different antibiotic therapies for CDI in patients with IBD.  Methods: A systematic review and meta-analysis were conducted according to PRISMA 2020 guidelines. Searches were performed in MEDLINE, EMBASE, PubMed, Epistemonikos, and the Cochrane Library through October 2024. Observational studies and clinical trials comparing antibiotic regimens in adult IBD patients with CDI were included. Data on recurrence, clinical outcomes, colectomy, and mortality were extracted. Random-effects meta-analysis was performed when appropriate.  Results: Nine studies involving 643 patients met inclusion criteria. Recurrence occurred in 17.4% of patients treated with metronidazole and 8.2% of those treated with vancomycin. In the meta-analysis of four studies (n=214), vancomycin showed a trend toward lower recurrence, although not statistically significant (OR 0.55; 95%CI 0.15-1.99; P=0.36; I2=66%). Mortality was low and similar between groups, and colectomy occurred exclusively in patients with ulcerative colitis. Data on clinical success and adverse events were heterogeneously reported and summarized narratively.  Conclusion: Vancomycin may be associated with lower recurrence in higher-risk IBD patients; however, available evidence remains limited and heterogeneous. Treatment decisions should be individualized, and further prospective, IBD-specific studies are needed to clarify optimal management strategies.<\/jats:p>","DOI":"10.1590\/s0004-2803.24612025-145","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:26:18Z","timestamp":1784546778000},"source":"Crossref","is-referenced-by-count":0,"title":["MANAGEMENT OF CLOSTRIDIOIDES DIFFICILE INFECTION IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF ANTIBIOTIC EFFICACY"],"prefix":"10.1590","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7258-8155","authenticated-orcid":false,"given":"Isadora Brand\u00e3o","family":"PELUCIO","sequence":"first","affiliation":[{"name":"Universidade Federal de Juiz de Fora,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6619-136X","authenticated-orcid":false,"given":"Carla","family":"MALAGUTI","sequence":"additional","affiliation":[{"name":"Universidade Federal de Juiz de Fora,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1160-2456","authenticated-orcid":false,"given":"T\u00falio Medina Dutra de","family":"OLIVEIRA","sequence":"additional","affiliation":[{"name":"Universidade Federal de Juiz de Fora,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7020-2903","authenticated-orcid":false,"given":"Karoline Maria de Souza Marques","family":"CHITARRA","sequence":"additional","affiliation":[{"name":"Universidade Federal de Juiz de Fora,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0843-5709","authenticated-orcid":false,"given":"Maria Cristina Vasconcellos","family":"FURTADO","sequence":"additional","affiliation":[{"name":"Universidade Federal de Juiz de Fora,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1527-0663","authenticated-orcid":false,"given":"J\u00falio Maria Fonseca","family":"CHEBLI","sequence":"additional","affiliation":[{"name":"Universidade Federal de Juiz de Fora,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2026]]},"reference":[{"key":"ref1","first-page":"2769","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng SC","year":"2018","journal-title":"Lancet"},{"key":"ref2","first-page":"280","article-title":"Clostridioides difficile infection: an update","volume":"32","author":"Salvati F","year":"2024","journal-title":"Infez Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/MIB.0000000000000537","article-title":"Risk factors for Clostridium difficile infection among patients with inflammatory bowel disease","volume":"21","author":"Allegretti JR","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"ofad232","DOI":"10.1093\/ofid\/ofad232","article-title":"Clostridioides difficile infection: clinical practice and health outcomes in six large hospitals in Australia","volume":"10","author":"Stewart AG","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2024.08.003","article-title":"Comparative effectiveness of vancomycin and metronidazole on event-free survival in patients with Clostridioides difficile","volume":"30","author":"Conrad J","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"ESCMID 2021 update on the treatment of Clostridioides difficile infection","volume":"27","author":"van Prehn J","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"ref7","article-title":"2021 IDSA\/SHEA clinical practice guidelines for Clostridioides difficile infection in adults and children","volume":"73","author":"Johnson S","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/phar.2734","article-title":"Fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: a meta-analysis","volume":"42","author":"Liao JX","year":"2022","journal-title":"Pharmacotherapy"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cgh.2006.12.027","article-title":"Incidence of Clostridium difficile infection in inflammatory bowel disease","volume":"5","author":"Rodemann JF","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/ibd.20500","article-title":"Clostridium difficile and inflammatory bowel disease","volume":"14","author":"Issa M","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/ajg.2016.187","article-title":"Recurrence of Clostridium difficile infection in patients with inflammatory bowel disease: the RECIDIVISM study","volume":"111","author":"Razik R","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"ref12","first-page":"1","article-title":"Antibiotics for treatment of Clostridium difficile infection in hospitalized patients with inflammatory bowel disease","volume":"20","author":"Horton HA","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"ref13","article-title":"Metronidazole treatment of Clostridium difficile infection in inflammatory bowel disease is associated with a high risk of treatment failure and recurrence","author":"Hamid F","year":"2026","journal-title":"AGA Abstracts"},{"key":"ref14","article-title":"Treatment for Clostridium difficile infection in inflammatory bowel disease diagnosed in the outpatient setting: metronidazole vs. vancomycin","author":"Bownik H","year":"2026","journal-title":"AGA Abstracts"},{"key":"ref15","first-page":"3532","article-title":"Diagnostic modality of Clostridioides difficile infection predicts treatment response and outcomes in inflammatory bowel disease","volume":"65","author":"Gupta A","year":"2020","journal-title":"Dig Dis Sci"},{"key":"ref16","first-page":"889","article-title":"Clostridium difficile in inflammatory bowel disease: which treatment regimen is superior?","volume":"154","author":"Dharbhamulla N","year":"2018","journal-title":"Inflammatory Bowel Diseases"},{"key":"ref17","first-page":"50","article-title":"Clostridium difficile infection in pre-existing inflammatory bowel disease: a case series","volume":"11","author":"Campbell I Amin A","year":"2017","journal-title":"Journal of Crohn\u2019s & Colitis"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":["Efic\u00e1cia da terapia antibi\u00f3tica no tratamento da infec\u00e7\u00e3o por Clostridioides difficile em pacientes com doen\u00e7a inflamat\u00f3ria intestinal: revis\u00e3o sistem\u00e1tica"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0004-28032026000105009&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:26:21Z","timestamp":1784546781000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032026000105009&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":17,"alternative-id":["S0004-28032026000105009"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.24612025-145","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e25145"}}